concept · intermediate · partly written
Graft rejection and immunosuppression: why donor cells are attacked and how that is managed
Cells from a donor carry foreign HLA identity tags, so the recipient immune system attacks them unless it is suppressed, the donor is matched, or the cells are edited; a patient own cells avoid this.
Also called: rejection, allogeneic rejection, HLA mismatch
Rejection in brief
Every cell carries identity tags called HLA. If cells come from another person the recipient T cells, natural killer cells and antibodies can recognise them as foreign. Cells from the patient own body carry the patient tags and are not attacked for that reason. 1
Reported, not yet replicated
Three ways donor cells are attacked more
Reviewing the problem for induced pluripotent stem cell products, a 2021 paper (abstract read here) describes HLA matching, and describes natural killer cells attacking cells that lack the self HLA class I tags. Recipient T cells attack foreign HLA, and antibodies can attack donor antigens. 1
Reported, not yet replicated
How it is handled in an approved product more
The FDA basis document for Lantidra (donor islets given into the portal vein of the liver) states that the cells are kept alive by immunosuppressive drugs, whose risks are among the adverse events listed. For a patient own engineered cells such as CAR T, the foreign part is the mouse-derived binder rather than HLA: the FDA 2017 tisagenlecleucel review reported pre-infusion antibodies against it in 86% of patients with no apparent effect on expansion or response. 23
Reported, not yet replicated
Editing cells to hide deep
One reported man received islets edited with CRISPR-Cas12b and lentiviral transduction in forearm muscle, without immunosuppression; the abstract reports no immune response and no serious adverse events at 12 weeks. It is one patient and a short follow-up. 4
Reported, not yet replicated
Plain answer
Why it matters
Real numbers
Anti-CAR antibodies
FDA review of tisagenlecleucel: antibodies against the CAR binder in 86% of patients before infusion and 37% induced, with no apparent effect on expansion or response. 3
Reported, not yet replicated
Teach this
In one sentence
Donor cells carry foreign HLA tags and are rejected unless the immune system is suppressed or the cells are changed. 1
Reported, not yet replicated
The five-minute version
HLA tags tell T cells and natural killer cells whether a cell belongs to the body. Donor cells are foreign; drugs, matching or editing are the three tried routes, each with cost or limits. Patient own cells avoid this, though engineered parts can still be foreign. 1
Reported, not yet replicated
What a listener will ask
Why are CAR T cells made from the patient own cells?
They carry the patient HLA, so there is no donor mismatch.
Do donor products need lifelong drugs?
Lantidra does, per the FDA basis document.
Can cells be edited to hide?
One reported patient received edited islets without immunosuppression; it is a single case.
The common wrong idea
The body always rejects any engineered or implanted cells.
Rejection depends on whose HLA the cells carry; own cells avoid it, donor cells need suppression, matching or editing.
The one citation to hand over: 1
Still open here
- Is HLA matching enough in practice to reduce immunosuppression? No opened source gives evidence.
Not yet written: Equation.
Linked from
Sources
- Flahou, C., Morishima, T., Takizawa, H., et al.. Fit-for-all iPSC-derived cell therapies and their evaluation in humanized mice with NK cell immunity. Frontiers in Immunology (2021). review; opened 2026-11-17 all records citing this
- U.S. Food and Drug Administration. Summary Basis for Regulatory Action: LANTIDRA (donislecel-jujn). FDA (2023). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- FDA Summary Basis for Regulatory Action: Kymriah (tisagenlecleucel). FDA (2017). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Carlsson, P.-O., Hu, X., Scholz, H., et al.. Survival of transplanted allogeneic beta cells with no immunosuppression. New England Journal of Medicine (2025). paper; opened 2026-11-17 all records citing this
History of this record (2)
This record has been changed 2 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/concepts/graft-rejection-and-immunosuppression.json